We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

236 hedge funds and large institutions have $3B invested in Array Biopharma Inc in 2018 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 74 increasing their positions, 74 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more call options, than puts

Call options by funds: $31.1M | Put options by funds: $12.4M

111% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 27

13% more funds holding

Funds holding: 208 → 236 (+28)

13% more funds holding in top 10

Funds holding in top 10: 8 → 9 (+1)

0% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 74

4% less capital invested

Capital invested by funds: $3.11B → $3B (-$111M)

Holders
236
Holders Change
+28
Holders Change %
+13.46%
% of All Funds
5.26%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.2%
New
57
Increased
74
Reduced
74
Closed
27
Calls
$31.1M
Puts
$12.4M
Net Calls
+$18.7M
Net Calls Change
+$10.1M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$99.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$69.7M
3
GPP
Great Point Partners
Connecticut
+$28.1M
4
Franklin Resources
Franklin Resources
California
+$23.1M
5
Goldman Sachs
Goldman Sachs
New York
+$21.1M

Top Sellers

1
O
OrbiMed
New York
-$73.1M
2
State Street
State Street
Massachusetts
-$25.4M
3
BI
BVF Inc
California
-$23.5M
4
IBT
International Biotechnology Trust
United Kingdom
-$11.7M
5
Deutsche Bank
Deutsche Bank
Germany
-$11.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
251
BlueCrest Capital Management
Jersey
– -$160K -10,498 Closed
QT
252
Quantbot Technologies
New York
– -$116K -7,639 Closed
APP
253
Avantax Planning Partners
Iowa
– -$96K -6,305 Closed
MYIA
254
Mount Yale Investment Advisors
Colorado
– -$30K -1,739 Closed
TRCT
255
Tower Research Capital (TRC)
New York
– -$15K -1,007 Closed
TA
256
Townsend & Associates
Colorado
– -$8K -555 Closed
CPIG
257
Chicago Partners Investment Group
Illinois
– -$8K -550 Closed
SCM
258
Southport Capital Management
Tennessee
– -$8K -500 Closed
KF
259
Krilogy Financial
Missouri
– -$5K -300 Closed
SPIA
260
Steward Partners Investment Advisory
New York
– -$2K -150 Closed
AIA
261
Alera Investment Advisors
Illinois
– +$288 +19 New
FHA
262
Flagship Harbor Advisors
Massachusetts
– +$910 +60 New
7 8 9 10
11

ARRY Hedge Fund Activity: Q4 2018 in Review

236 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2018, worth a combined $3B — down 3.6% from $3.11B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new ARRY positions and 27 closed out — a net gain of 30 holders — while 74 added to existing stakes and 74 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $99.2M. The largest seller was OrbiMed, exiting entirely with an estimated $73.1M sold.

  • 236 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2018, up from 208 in Q3 2018.
  • Funds reported $3B of Array Biopharma Inc stock for Q4 2018, down 3.6% quarter-over-quarter.
  • 57 funds opened new Array Biopharma Inc positions in Q4 2018 and 27 closed out, a net change of +30 holders.
  • The largest Array Biopharma Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $99.2M added.
  • The largest Array Biopharma Inc seller in Q4 2018 was OrbiMed, an estimated $73.1M sold.

Based on aggregated 13F filings for Q4 2018.